| An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment CH GeurtsvanKessel, NMA Okba, Z Igloi, S Bogers, CWE Embregts, ... Nature communications 11 (1), 3436, 2020 | 373 | 2020 |
| Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study J Gregson, M Tang, N Ndembi, RL Hamers, SY Rhee, VC Marconi, ... The Lancet infectious diseases 16 (5), 565-575, 2016 | 299 | 2016 |
| Convalescent plasma for COVID-19. A randomized clinical trial A Gharbharan, CCE Jordans, C Geurtsvankessel, JG den Hollander, ... MEDRxiv, 2020.07. 01.20139857, 2020 | 281 | 2020 |
| Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection A Gharbharan, CCE Jordans, C GeurtsvanKessel, JG den Hollander, ... Nature communications 12 (1), 3189, 2021 | 178 | 2021 |
| Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial I Wijting, C Rokx, C Boucher, J van Kampen, S Pas, T de Vries-Sluijs, ... The lancet HIV 4 (12), e547-e554, 2017 | 145 | 2017 |
| High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis E Hoornenborg, L Coyer, A Boyd, RCA Achterbergh, MFS van der Loeff, ... Journal of hepatology 72 (5), 855-864, 2020 | 72 | 2020 |
| A highly virulent variant of HIV-1 circulating in the Netherlands C Wymant, D Bezemer, F Blanquart, L Ferretti, A Gall, M Hall, T Golubchik, ... Science 375 (6580), 540-545, 2022 | 67 | 2022 |
| HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study C Smit, A Boyd, BJA Rijnders, TJW van de Laar, EM Leyten, WF Bierman, ... The Lancet HIV 8 (2), e96-e105, 2021 | 64 | 2021 |
| SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model BL Haagmans, D Noack, NMA Okba, W Li, C Wang, T Bestebroer, ... The Journal of Infectious Diseases 223 (12), 2020-2028, 2021 | 60 | 2021 |
| Association of convalescent plasma treatment with clinical status in patients hospitalized with COVID-19: a meta-analysis AB Troxel, E Petkova, K Goldfeld, M Liu, T Tarpey, Y Wu, D Wu, A Agarwal, ... JAMA Network Open 5 (1), e2147331-e2147331, 2022 | 54 | 2022 |
| Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning YM Mueller, TJ Schrama, R Ruijten, MWJ Schreurs, DGB Grashof, ... Nature communications 13 (1), 915, 2022 | 53 | 2022 |
| T cell toxicity of HIV latency reversing agents M Zhao, E De Crignis, C Rokx, A Verbon, T van Gelder, T Mahmoudi, ... Pharmacological research 139, 524-534, 2019 | 48 | 2019 |
| Small molecule inhibitors of BAF; a promising family of compounds in HIV-1 latency reversal M Stoszko, E De Crignis, C Rokx, MM Khalid, C Lungu, RJ Palstra, ... EBioMedicine 3, 108-121, 2016 | 48 | 2016 |
| Unified European support framework to sustain the HIV cascade of care for people living with HIV including in displaced populations of war-struck Ukraine M Vasylyev, A Skrzat-Klapaczyńska, JI Bernardino, O Săndulescu, ... The Lancet HIV 9 (6), e438-e448, 2022 | 47 | 2022 |
| Coronavirus disease 2019 convalescent plasma outpatient therapy to prevent outpatient hospitalization: a meta-analysis of individual participant data from 5 randomized trials AC Levine, Y Fukuta, MA Huaman, J Ou, BR Meisenberg, B Patel, ... Clinical Infectious Diseases 76 (12), 2077-2086, 2023 | 46 | 2023 |
| Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: an international collaboration SY Rhee, V Varghese, SP Holmes, GU Van Zyl, K Steegen, MA Boyd, ... EBioMedicine 18, 225-235, 2017 | 46 | 2017 |
| Interferon-α2 auto-antibodies in convalescent plasma therapy for COVID-19 MP Raadsen, A Gharbharan, CCE Jordans, AZ Mykytyn, MM Lamers, ... Journal of clinical immunology, 1-8, 2022 | 39 | 2022 |
| Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir S Rao, C Lungu, R Crespo, TH Steijaert, A Gorska, RJ Palstra, HAB Prins, ... Nature Communications 12 (1), 2475, 2021 | 39 | 2021 |
| Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study KS Hensley, MJ Jongkees, D Geers, CH GeurtsvanKessel, YM Mueller, ... PLoS medicine 19 (10), e1003979, 2022 | 38 | 2022 |
| Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy IEA Wijting, FWNM Wit, C Rokx, EMS Leyten, SH Lowe, K Brinkman, ... EClinicalMedicine 17, 2019 | 34 | 2019 |
Jairo Jamith Palacios RozoDocente Investigador - Universidad Colegio Mayor de Cundinamarca在 unicolmayor.edu.co 的电子邮件经过验证
Jairo Jamith Palacios RozoDocente Investigador - Universidad Colegio Mayor de Cundinamarca在 unicolmayor.edu.co 的电子邮件经过验证